Gilead Sciences Inc (GILD)

[biopharm]

I agree but also hope Gilead is smart enough to dig deep into how PS Targeting not only helps solid tumors along with blood disorders, but Neuroscience they can branch into.

Gilead's CART cell program can expand with PS Targeting and if they only see the other patents surrounding GLYT1 and how memory may also be a driving force in a deal especially when others are already in beginning stages with building patents ...but those patents may be questioned in how they discovered certain facts, unless PS Targeting was involved and we don't see it publicly, yet.

Justia Patents Patents Assigned to Dart NeuroScience (Cayman) Ltd.


Patents Assigned to Dart NeuroScience (Cayman) Ltd.
SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS
Publication number: 20170334846
Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
Type: Application
Filed: November 3, 2015
Publication date: November 23, 2017
Applicant: Dart Neuroscience (Cayman) Ltd.
Inventors: Jillian Basinger, Brett Bookser, Mi Chen, Andrew Hudson, James Na, Joel Renick, Vincent Santora
Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
Patent number: 9795591
Abstract: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.